Kaletra
Kaletra Brand names, Kaletra Analogs
Kaletra Brand Names Mixture
- Kaletra (Lopinavir + Ritonavir)
Kaletra Chemical_Formula
C37H48N6O5S2
Kaletra RX_link
http://www.rxlist.com/cgi/generic2/ritonavirsol.htm
Kaletra fda sheet
Kaletra msds (material safety sheet)
Kaletra Synthesis Reference
No information avaliable
Kaletra Molecular Weight
720.946 g/mol
Kaletra Melting Point
No information avaliable
Kaletra H2O Solubility
Practically insoluble
Kaletra State
Solid
Kaletra LogP
4.941
Kaletra Dosage Forms
Capsule (100 mg); Solution (80 mg/mL of ritonavir)
Kaletra Indication
Indicated in combination with other antiretroviral agents for the treatment of HIV-infection.
Kaletra Pharmacology
Ritonavir is a protease inhibitor with activity against Human Immunodeficiency Virus Type 1 (HIV-1). Protease inhibitors block the part of HIV called protease. HIV-1 protease is an enzyme required for the proteolytic cleavage of the viral polyprotein precursors into the individual functional proteins found in infectious HIV-1. Ritonavir binds to the protease active site and inhibits the activity of the enzyme. This inhibition prevents cleavage of the viral polyproteins resulting in the formation of immature non-infectious viral particles. Protease inhibitors are almost always used in combination with at least two other anti-HIV drugs.
Kaletra Absorption
The absolute bioavailability of ritonavir has not been determined.
Kaletra side effects and Toxicity
Human experience of acute overdose with NORVIR is limited. One patient in clinical trials took NORVIR 1500 mg/day for two days. The patient reported paresthesias which resolved after the dose was decreased. A post-marketing case of renal failure with eosinophilia has been reported with ritonavir overdose. The approximate lethal dose was found to be greater than 20 times the related human dose in rats and 10 times the related human dose in mice.
Kaletra Patient Information
No information avaliable
Kaletra Organisms Affected
Human immunodeficiency virus
